Transfusion use in patients with rare blood cancer (myelodysplastic syndromes)
Not Applicable
Completed
- Conditions
- Myelodysplastic syndromesCancer
- Registration Number
- ISRCTN38059137
- Lead Sponsor
- Karolinska Institute
- Brief Summary
2021 Results article in https://pubmed.ncbi.nlm.nih.gov/33210286/ (added 02/09/2021)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 2858
Inclusion Criteria
Adult patients with a confirmed histopathological diagnosis of MDS in the time period from 2008-2017, living in Sweden
Exclusion Criteria
Reseachers will restrict the analyses to patients with known WHO-subgroup and IPSS/IPSS-R risk group respectively
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method